Cathie Wood’s ARK Invest published its daily trades for Friday, Oct. 9, 2026. The trades covered several of its exchange-traded funds.
ARK sold a number of well-known technology and growth names. At the same time, it added to a wide range of biotech companies.
DraftKings (DKNG) and CareDx (CDNA) Sales
The largest sale of the day was DraftKings. ARK sold 397,016 shares through its ARKW and ARKF funds, worth about $7.89 million.
This continues a recent trend. ARK sold large amounts of DraftKings earlier in the week as well.
ARK also sold 57,911 shares of CareDx through ARKG. The shares were worth $3.60 million. ARK has sold CareDx steadily over the past week.
Tech and Space Stocks Trimmed
ARK sold 22,276 shares of Space Exploration Technologies Corp, known as SpaceX. The sale was worth $3.58 million.
The ARK Innovation ETF (ARKK), known as ARKK, reduced its stakes in five companies. These were SpaceX, Advanced Micro Devices (AMD), Alphabet (GOOGL), Robinhood Markets (HOOD) and Shopify (SHOP).
The sales went beyond technology. ARKF sold the ARK 21Shares Bitcoin (BTC.X) ETF (ARKB) and DraftKings. ARKG cut its positions in Personalis (PSNL) and CareDx.
The ARK Space & Defense Innovation ETF (ARKX) sold Iridium Communications (IRDM).
ARKG Adds Biotech Stocks
Most of the buying took place in ARKG. The fund added to many biotech companies instead of focusing on one stock.
ARK bought 21,487 shares of CRISPR Therapeutics (CRSP), worth $1.08 million. It also bought 48,171 shares of Intellia Therapeutics (NTLA) for $606,954. Both are gene-editing companies, along with Beam Therapeutics (BEAM), which ARK also added.
ARK bought 56,096 shares of Nurix Therapeutics, valued at $1.24 million. It continues to build that position.
The fund also bought 7,210 shares of Guardant Health (GH) for $1.19 million. Other purchases included Kymera Therapeutics (KYMR), Compass Pathways (CMPS), Alamar Biosciences and Freenome.
The ARK Autonomous Technology & Robotics ETF (ARKQ) bought Symbotic (SYM) and Kodiak AI.
Fund and Stock Performance
ARKG closed up more than 4% in Friday’s regular trading session. It rose nearly 0.4% in after-hours trading.
CRISPR Therapeutics gained 5.85% on the day. Beam Therapeutics rose 4.47%, and Compass Pathways rose 4.62%.
DraftKings fell 1.46% and AMD fell 2.03%. Retail sentiment on Stocktwits around ARKG was bearish at the time of writing.
Comments
Log in or sign up to join the conversation.